Italia markets close in 6 hours

Affimed N.V. (AFMD)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
5,07-0,16 (-3,06%)
Alla chiusura: 04:00PM EDT
5,32 +0,25 (+4,93%)
Dopo ore: 07:48PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente5,23
Aperto5,29
Denaro5,01 x 100
Lettera5,14 x 100
Min-Max giorno5,07 - 5,29
Intervallo di 52 settimane2,24 - 11,10
Volume89.420
Media Volume92.375
Capitalizzazione77,203M
Beta (5 anni mensile)2,09
Rapporto PE (ttm)N/D
EPS (ttm)-7,53
Prossima data utili21 mag 2024 - 27 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A22,25
  • GlobeNewswire

    Affimed Announces Listing Transfer to Nasdaq Capital Markets

    MANNHEIM, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received approval from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its shares from the Nasdaq Global Market to the Nasdaq Capital Market. This transfer is effective as of the opening of bu

  • GlobeNewswire

    Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

    MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract with a comparison of NK cell redirected by the Company’s innate cell engagers (ICE®) versus CAR-NK cells has been accepted for poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be he

  • GlobeNewswire

    Affimed to Present at the Cantor Global Healthcare Conference 2023

    MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Financial Officer, Angus Smith, will participate in a fireside chat at the Cantor Global Healthcare Conference 2023 on Thursday, September 28, 2023 at 1:15 p.m. Eastern Daylight Time / 19:15 Central European Time. A live webcast of the present